Immunotherapy as an effective tool in allergy treatment

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 53, Issue 5, 1998, Pages 461-472

  Malling, H J ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Asthma; Efficacy; Immunotherapy; Rhinitis; Side effects

Indexed keywords

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; CONFERENCE PAPER; DESENSITIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0031838266     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1998.tb04082.x     Document Type: Conference Paper

References (84)

1. Müller U, Mosbech H, editors. EAACI position paper. Immunotherapy with Hymenoptera venoms. Allergy 1993; 48 Suppl 14:37-46.
2. Mailing H-J, Wecke B, editors. EAACI position paper. Immunotherapy. Allergy 1993;48 Suppl 14:9-45.
3. Mailing H-J. New ideas in allergen-specific immunotherapy. Am J Rhinol 1990;4:155-8.
4. Dreborg S, Frew A, editors. Allergen standardization and skin tests. Allergy 1993;48 Suppl 14:49-82.
5. van Metre TE, Adkinson NF, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:288-97.
6. Hirsch SR, Kalbfleisch JH, Golbert TM, et al. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol 1981;68:133-55.
7. Metzger WJ, Dorminey HC, Richerson HB, Weiler JM, Donnelly A, Moran D. Clinical and immunologic evaluation of glutaraldehyde-modified, tyrosine-absorbed short ragweed extract: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1981;68:442-8.
8. Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy 1981;36:309-17.
9. Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R. A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:494-9.
10. Lee LK, Kniker WT, Campos T. Aggressive coseasonal immunotherapy in mountain cedar pollen allergy. Arch Otolaryngol 1982;108:787-94.
11. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70: 248-60.
12. van Metre TE, Adkinson NF, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:181-93.
13. Grammer LC, Shaughnessy MA; Suszko IM, Shaughnessy JJ, Patterson R. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72: 448-53.
14. Blainey AD, Phillips MJ, Oilier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. Allergy 1984;39:521-8.
15. Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R. Asthma as a variable in a study of immunotherapy for allergic rhinitis. J Allergy Clin Immunol 1984; 73:557-60.
16. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 283-90.
17. Juniper EF, Roberts RS, Kennedy LK, et al. Polyethylene glycol-modified ragweed pollen extract in rhinoconjunctivitis. J Allergy Clin Immunol 1985;75:578-85.
18. Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R. A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Immunol 1986;78:1180-4.
19. Meriney DK, Kothari H, Chinoy P, Grieco MH. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:34-8.
20. Bousquet J, Frank E, Soussana M, Hejjaoui A, Maasch HJ, Michel FB. Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy. Int Arch Allergy Appl Immunol 1987;82:550-2.
21. Bousquet J, Hejjaoui A, Skassa Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-8.
22. Grammer LC, Shaughnessy MA, Bernhard MI, et al. The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis. J Allergy Clin Immunol 1987;80:177-83.
23. Bousquet J, Maarch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-46.
24. Ewan PW, Alexander MM, Snapc C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:501-8.
25. Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546-56.
26. Corrado OJ, Pastorello E, Oilier S, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac®) in patients with perennial rhinitis. I. Clinical aspects. Allergy 1989;44:108-15.
27. Fling JA, Ruff ME, Parker WA, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101-9.
28. McHugh SM, Ewan PW. Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy 1989;19:327-34.
29. Parker WA, Whisman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84: 667-77.
30. Bousquet J, Hejjaoui A, Soussana M, Michel F-B. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:490-7.
31. Horst M, Hejjaoui A, Horst V, Michel F-B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-72.
32. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Polinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 1990;85:606-11.
33. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:521-32.
34. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43-53.
35. Iliopoulos O, Proud D, Franklin Adkinson N, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergens: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991;87:855-66.
36. Litwin A, Pesce AJ, Fischer T, Michael M. Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment. Clin Exp Allergy 1991;21:457-65.
37. Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JMR. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergy 1991;46:335-48.
38. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-9.
39. Brunet C, Bédard P-M, Lavoie A, Jobin M, Hébert J. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 1992;89:76-86.
40. Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:281-90.
41. Karmakar PR, Das A, Chatterjee BP. Placebo-controlled immunotherapy with Cocos nucifera pollen extract. Int Arch Allergy Immunol 1994;103:194-201.
42. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994;49:13-21.
43. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy 1995;25:149-58.
44. Dolz I, Martínez-Cócera C, Bartolomé JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500.
45. Ariano R, Panzani RC, Augeri G. Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae Taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol Immunopathol (Madr) 1997; 25:23-9.
46. Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy 1997;52:65-74.
47. Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:23-9.
48. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 283-90.
49. Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine-absorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984;74:524-35.
50. Dreborg S, Agrell B, Foucard T, Kjellman N-IM, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. Allergy 1986;41: 131-40.
51. Mailing H-J, Dreborg S, Wecke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507-19.
52. Reid MJ, Moss RB, Hsu Y-P, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590-600.
53. Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986;57:173-9.
54. Bousquet J, Maasch H, Hejjaoui A, et al. Double blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546-56.
55. Kuna P, Alam R, Kumanska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989;83:816-24.
56. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:490-7.
57. Machiels JJ, Somville MA, Lebrun PM, Lebccque SJ, Jacquemin MG, Saint-Remy J-MR. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990;85:1024-35.
58. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quirós A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-66.
59. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
60. Pickler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-83.
61. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997;27:860-7.
62. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:853-9.
63. Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74:230-9.
64. Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984;53:85-8.
65. Bousquet J, Calvayrac P, Guérin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76:734-44.
66. Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478-87.
67. van Metre TE, Marsh DG, Adkinson NF, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82:1055-68.
68. Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989;63:127-35.
69. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992; 47:249-54.
70. van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronvssinus). Eur Respir J 1992; 5:318-22.
71. Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995;50:925-30.
72. Adkinson FN, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.
73. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995;95:923-32.
74. Bronsky WA, Dockhorn RJ, Meltzer EO, et al. Fluticasonc propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-21.
75. Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-43.
76. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92.
77. Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Rcspir J 1992;5:945-52.
78. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-83.
79. Ayres JG, Bateman ED, Lundbäck B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8:579-86.
80. König P, Schaffer J. The effect of drug therapy on long-term outcome of childhood asthma: a possible preview of the international guidelines. J Allergy Clin Immunol 1996; 98:1103-11.
81. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993;92:6-15.
82. Stewart GE II, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90: 567-78.
83. Hejjaoui J, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992; 89:925-33.
84. Tabar AI, García BE, Rodríguez A, Olaguibel JM. Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-3.